NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
Eli Lilly and Company
Novartis
M.D. Anderson Cancer Center
Indiana University
Children's Oncology Group
AstraZeneca